Tarsus director granted RSUs and stock options

Tarsus Pharmaceuticals director Wendy L. Yarno received new equity awards as part of her non-employee director compensation for the company’s 2026 annual meeting.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director Wendy L. Yarno received new equity awards as part of her non-employee director compensation for the company’s 2026 annual meeting. She was granted 1,209 and 2,417 restricted stock units, each RSU equal to one common share, plus an option for 3,837 shares at an exercise price of $64.34. The option vests in full one year after grant, while the RSUs vest either fully after one year or in four scheduled installments, all subject to continued board service. These are compensation grants, not open-market share purchases or sales.

Insider Trade Summary

Grant/Award: 7,463 shares

Grant/Award 3 txns

Insider YARNO WENDY L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,837	$0.00	$0.00
Grant/Award	Restricted Stock Units	2,417	$0.00	$0.00
Grant/Award	Restricted Stock Units	1,209	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 3,837 contracts (Direct); Restricted Stock Units — 3,626 contracts (Direct)

Footnotes (4)

1. F1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
4. F4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Key Figures

RSU grant 1: 1,209 units RSU grant 2: 2,417 units Stock option shares: 3,837 shares +2 more

5 metrics

RSU grant 1 1,209 units Restricted Stock Units tied to 2026 annual meeting service

RSU grant 2 2,417 units Restricted Stock Units vesting in four scheduled installments

Stock option shares 3,837 shares Annual non-employee director option grant

Option exercise price $64.34 per share Exercise price for 3,837-share stock option grant

Option expiration June 24, 2036 Expiration date of the granted stock option

Key Terms

Restricted Stock Unit, RSU, Stock Option (right to buy), non-employee director, +1 more

5 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an expiration date of 2036-06-24"

non-employee director financial

"granted in connection with the Reporting Person's service as a non-employee director"

annual meeting of stockholders financial

"as of the Company's 2026 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tarsus (TARS) director Wendy L. Yarno report on this Form 4?

Director Wendy L. Yarno reported equity compensation grants, not market trades. She received restricted stock units and a stock option tied to her service as a non-employee director following Tarsus Pharmaceuticals’ 2026 annual meeting of stockholders.

How many restricted stock units did Wendy L. Yarno receive from Tarsus (TARS)?

She received two RSU grants: 1,209 units and 2,417 units. Each restricted stock unit represents a contingent right to receive one share of Tarsus Pharmaceuticals common stock if the applicable vesting conditions tied to board service are satisfied.

What stock option grant did Wendy L. Yarno receive from Tarsus (TARS)?

She was granted a stock option covering 3,837 shares of Tarsus Pharmaceuticals common stock at an exercise price of $64.34. The option was issued as her annual non-employee director option grant for 2026, with vesting based on continued board service.

When do Wendy L. Yarno’s Tarsus (TARS) stock option and RSUs vest?

The annual option vests in full on the one-year anniversary of the grant date. One RSU grant vests fully after one year, while the other vests in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, all requiring continued service.

Do Wendy L. Yarno’s reported Tarsus (TARS) transactions involve open-market buying or selling?

No, the Form 4 reflects equity awards granted as compensation. The transactions are coded as grants (Code A) of restricted stock units and a stock option, not open-market purchases or sales of Tarsus Pharmaceuticals common stock.

What does each RSU granted to Wendy L. Yarno by Tarsus (TARS) represent?

Each restricted stock unit represents a contingent right to receive one share of Tarsus Pharmaceuticals common stock. Delivery of the underlying shares depends on satisfaction of vesting conditions tied to Wendy L. Yarno’s ongoing service as a non-employee director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YARNO WENDY L

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$64.34	06/25/2026		A		3,837		(1)	06/24/2036	Common Stock	3,837	$0	3,837	D
Restricted Stock Units	(2)	06/25/2026		A		2,417		(3)	(3)	Common Stock	2,417	$0	2,417	D
Restricted Stock Units	(2)	06/25/2026		A		1,209		(4)	(4)	Common Stock	1,209	$0	1,209	D

Explanation of Responses:

1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Remarks:

	/s/ Scott Sieckert, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)